- Home
- KF vs RCEL Comparison
KF vs RCEL Comparison
Compare KF & RCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KF
- RCEL
- Stock Information
- Founded
- KF 1984
- RCEL N/A
- Country
- KF United States
- RCEL United States
- Employees
- KF N/A
- RCEL N/A
- Industry
- KF Investment Managers
- RCEL Medical/Dental Instruments
- Sector
- KF Finance
- RCEL Health Care
- Exchange
- KF Nasdaq
- RCEL Nasdaq
- Market Cap
- KF 128.4M
- RCEL 107.8M
- IPO Year
- KF N/A
- RCEL N/A
- Fundamental
- Price
- KF $36.21
- RCEL $3.68
- Analyst Decision
- KF
- RCEL Buy
- Analyst Count
- KF 0
- RCEL 5
- Target Price
- KF N/A
- RCEL $11.80
- AVG Volume (30 Days)
- KF 18.4K
- RCEL 246.2K
- Earning Date
- KF 01-01-0001
- RCEL 11-06-2025
- Dividend Yield
- KF N/A
- RCEL N/A
- EPS Growth
- KF N/A
- RCEL N/A
- EPS
- KF N/A
- RCEL N/A
- Revenue
- KF N/A
- RCEL $74,884,000.00
- Revenue This Year
- KF N/A
- RCEL $20.40
- Revenue Next Year
- KF N/A
- RCEL $32.94
- P/E Ratio
- KF N/A
- RCEL N/A
- Revenue Growth
- KF N/A
- RCEL 38.32
- 52 Week Low
- KF $18.30
- RCEL $3.60
- 52 Week High
- KF $25.56
- RCEL $14.16
- Technical
- Relative Strength Index (RSI)
- KF 77.02
- RCEL 29.81
- Support Level
- KF $35.67
- RCEL $3.88
- Resistance Level
- KF $36.50
- RCEL $4.15
- Average True Range (ATR)
- KF 0.59
- RCEL 0.24
- MACD
- KF 0.25
- RCEL -0.10
- Stochastic Oscillator
- KF 100.00
- RCEL 2.23
About KF Korea Fund Inc. (The) New
Korea Fund Inc is a closed-end, non-diversified management investment company. Its investment objective is to seek long-term capital appreciation through investment in securities, equity securities, of Korean companies. Its portfolio consists of the different sectors such as the auto components, banks, beverages, chemicals, aerospace and defense, insurance, machinery, and Others.
About RCEL Avita Medical Inc.
Avita is a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult and paediatric patients in the US and an expanded indication for soft-tissue reconstruction. It is currently in rollout across the approximately 136 US burn centers. Despite having product approval in Australia, Europe, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region. However, it is expected to launch in Japan via distribution partner Cosmotec in second-half fiscal 2022. Avita is domiciled, and has its primary listing, in the US.